The methodological quality of systematic reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular degeneration: A systematic review of reviews

被引:22
|
作者
George, Pradeep Paul [1 ]
Molina, Joseph Antonio DeCastro [1 ]
Heng, Bee Hoon [1 ]
机构
[1] Natl Healthcare Grp, HQ, Singapore 149547, Singapore
关键词
Bevacizumab; intravitreal; neovascular age related macular degeneration; systemic; systematic review; systematic review of reviews; RANIBIZUMAB; PREVALENCE; DISEASES;
D O I
10.4103/0301-4738.138615
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To systematically collate and evaluate the evidence from recent SRs of bevacizumab for neo-vascular age related macular degeneration. Materials and Methods: Literature searches were carried out in Medline, Embase, Cochrane databases for all systematic reviews (SRs) on the effectiveness of bevacizumab for neo-vascular age related macular degeneration, published between 2000 and 2013. Titles and abstracts were assessed against the inclusion/exclusion criteria using Joanna Briggs Institute (JBI) study eligibility form. Data was extracted using the JBI data extraction form. The quality of the SRs was assessed using JBI critical appraisal checklist for SRs. Decisions on study eligibility and quality were made by two reviewers; any disagreements were resolved by discussion. Results: Nine relevant reviews were identified from 30 citations, of which 5 reviews fulfilled the review's inclusion criteria. All 5 reviews showed bevacizumab to be effective for neovascular AMD in the short-term when used alone or in combination with PDT or Pegaptanib. The average quality score of the reviews was 7; 95% confidence interval 6.2 to 7.8 (maximum possible quality score is 10). The selection and publication bias were not addressed in all included reviews. Three-fifth of the reviews had a quality score of 7 or lower, these reviews had some methodological limitations, search strategies were only identified in 2 (40%) reviews, independent study selection and quality assessment of included studies (4 (80%)) were infrequently performed. Conclusion: Overall, the reviews on the effectiveness of intravitreal/systemic bevacizumab for neovascular age-related macular generation (AMD) received good JBI quality scores (mean score = 7.0 points), with a few exceptions. The study also highlights the suboptimal reporting of SRs on this topic. Reviews with poor methodology may limit the validity of the reported results; hence efforts should be made to improve the design, reporting and publication of SRs across all journals.
引用
收藏
页码:761 / 767
页数:7
相关论文
共 50 条
  • [1] Intravitreal bevacizumab for neovascular age-related macular degeneration
    Ladewig M.S.
    Ziemssen F.
    Jaissle G.
    Helb H.-M.
    Scholl H.P.N.
    Eter N.
    Bartz-Schmidt K.U.
    Holz F.G.
    Der Ophthalmologe, 2006, 103 (6): : 463 - 470
  • [2] Intravitreal bevacizumab for neovascular age-related macular degeneration
    Ladewig, M. S.
    Ziemssen, F.
    Jaissle, G.
    Helb, H. -M.
    Scholl, H. P. N.
    Eter, N.
    Bartz-Schmidt, K. U.
    Holz, F. G.
    OPHTHALMOLOGE, 2006, 103 (06): : 463 - +
  • [3] Intravitreal bevacizumab (avastin) in treatment of neovascular age-related macular degeneration
    Lazic, Ratimir
    Gabric, Nikica
    Dekaris, Iva
    Saric, Borna
    Gavric, Morena
    COLLEGIUM ANTROPOLOGICUM, 2007, 31 : 77 - 81
  • [4] A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
    Schouten, Jan S. A. G.
    La Heij, Ellen C.
    Webers, Carroll A. B.
    Lundqvist, Igor J.
    Hendrikse, Fred
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (01) : 1 - 11
  • [5] Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events
    Weinstein, Orly
    Abu Tailakh, Muhammad
    Lifshitz, Tova
    Novack, Victor
    Levy, Jaime
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (01) : 66 - 71
  • [6] A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
    Jan S. A. G. Schouten
    Ellen C. La Heij
    Carroll A. B. Webers
    Igor J. Lundqvist
    Fred Hendrikse
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247
  • [7] Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration
    Emerson, M. Vaughn
    Lauer, Andreas K.
    Flaxel, Christina J.
    Wilson, David J.
    Francis, Peter J.
    Stout, J. Timothy
    Emerson, Geoffrey G.
    Schlesinger, Thomas K.
    Nolte, Susan K.
    Klein, Michael L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (04): : 439 - 444
  • [8] Systemic and intravitreal Bevacizumab (Avastin®) in neovascular age-related macular degeneration
    Michels, S.
    Prager, F.
    Geitzenauer, W.
    Lackner, B.
    Sacu, S.
    Weigert, G.
    Kriechbaum, K.
    Polak, K.
    Georgopoulos, M.
    Schmidt-Erfurth, U.
    SPEKTRUM DER AUGENHEILKUNDE, 2007, 21 (03) : 154 - 159
  • [9] Systemic and intravitreal Bevacizumab (Avastin®) in neovascular age-related macular degeneration
    Michels S.
    Prager F.
    Geitzenauer W.
    Lackner B.
    Sacu S.
    Weigert G.
    Kriechbaum K.
    Polak K.
    Georgopoulos M.
    Schmidt-Erfurth U.
    Spektrum der Augenheilkunde, 2007, 21 (3) : 154 - 159
  • [10] Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab
    Damkondwar, Deepali R.
    Srinivasan, Ramyaa
    Raman, Rajiv
    Kulothungan, Vaitheeswaran
    Sharma, Tarun
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (12) : 4376 - 4382